ÂÜÀòÂÒÂ×

Annalisa D’andrea is a Venture Partner at Longwood Fund and joined ImmuneID as President and Chief Scientific Officer in April 2021. She brings more than 25 years of experience in basic and translational research in immunology and inflammation and strategic and operational know how of drug discovery. She joins ImmuneID from Kiniksa Pharmaceuticals where she was Chief Scientific Officer. Prior to Kiniksa, she was Vice President and Global Head of Discovery for Immunology and Inflammation at Roche, where she was responsible for discovering and advancing multiple drug candidates to the clinic. Prior to Roche, Annalisa held roles of increasing responsibility at SRI International, including Executive Director and Section Head of Discovery Biology, where she was responsible for developing strategies to advance drugs through discovery and into development. Prior to that, she led the SRI International Center for Immunology, Inflammation, and Infectious Diseases, developing synergistic core expertise leveraging capabilities in vaccinology, autoimmunity, infectious diseases, and inflammation. Before she joined SRI, she worked at Chiron Vaccines in Siena, Italy, an American multinational biotechnology firm that was later acquired by Novartis and most recently by GSK.

Dr. D’Andrea was educated in Italy and in the United States. She received a Bachelor of Sciences, summa cum laude from the University of Siena in Italy. She earned her doctoral degree from the University of Florence while training at the Wistar Institute at the University of Pennsylvania. Her work as a graduate student culminated with the discovery of antigen-presenting cells as the main producers of IL-12. Her postdoctoral fellowship training was at the DNAX Research Institute in Palo Alto California under the mentorship of Dr. Lewis Lanier where she discovered one of the inhibitory receptors present on NK cells.